Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN®
San Diego, CA & Rotterdam, Netherlands- February 19, 2026 — SkylineDx today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its…
Melanoma Research
02/19/2026
Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN®
San Diego, CA & Rotterdam, Netherlands- February 19, 2026 — SkylineDx today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its…
|
|
02/05/2026
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate SAN CARLOS, Calif., Feb.…
|
|
01/23/2026
Moderna, Merck’s Skin Cancer Vaccine Shows Sustained Benefit in Five-Year Follow-Up
By Kamal Choudhury and Mariam E SunnyJanuary 20, 2026 3:52 PM EST Jan 20 (Reuters) – Moderna (MRNA.O), opens new tab and Merck…
|
01/21/2026
Reflecting on Melanoma Treatment in 2025 and Looking to the Future in 2026
The start of a new year is a time for reflection and looking to the future. This is an ideal…
|
01/13/2026
Improved Response to Immunotherapy with COVID-19 mRNA Vaccines
Introduction Data from a new study presented at the European Society for Medical Oncology (ESMO) meeting and published in Nature…
|
11/07/2025
You’re Not Out of Options: What to Do When First-Line Melanoma Treatment Fails
Melanoma treatment has advanced dramatically over the past decade, with immunotherapy and targeted therapies offering hope for many patients. However,…
|
11/02/2025
Immune Checkpoint Inhibition for Melanoma: A Focus on Veterans
Introduction Veterans have been shown to have a higher risk for melanoma compared to the general U.S. population due to…
|
11/02/2025
Overview of Melanoma in Veterans
Considerations Regarding Epidemiology, Risk Factors, Diagnosis, Prognosis, Survival, and Treatment Introduction Distinct health challenges affect veterans both during and after…
|
10/22/2025
SkylineDx Publishes Landmark MERLIN_001 Trial in JAMA Surgery Validating the Predictive Power of the Merlin CP-GEP Test in Melanoma
Rotterdam, The Netherlands – San Diego, CA – [October 22nd] – SkylineDx today announced that results from its landmark MERLIN_001…
|
|
10/07/2025
You’re Not Out of Options—What To Do After First Line Therapy Fails
Hearing that your treatment for melanoma has stopped working—or that you’ve had to stop because of side effects—can be overwhelming.…
|
Recent Posts
Mar. 03, 2026
Cancer is More Than a Diagnosis: Mind, Meaning, and Healing
Feb. 19, 2026
Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN®
Feb. 05, 2026
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma
Jan. 23, 2026
Moderna, Merck’s Skin Cancer Vaccine Shows Sustained Benefit in Five-Year Follow-Up
Jan. 21, 2026